We recently compiled a list of the Jim Cramer Highlighted Buying Opportunities in 13 Stocks. In this article, we are going to take a look at where Abbott Laboratories (NYSE:ABT) stands against the other stocks Jim Cramer recently talked about.
Jim Cramer, the host of Mad Money, took a moment on Wednesday to reflect on the latest market developments as earnings season progresses, sharing his thoughts on how investors can identify stocks that are unfairly punished and present solid buying opportunities.
“This market has the memory of a mayfly that creates a ton of opportunities so… I want to help you find them.”
READ ALSO Jim Cramer Shed Light on These 8 Stocks Recently and 12 Stocks on Jim Cramer’s Radar
Cramer stressed that time and again, he has seen growth stocks severely impacted by minor bits of bad news, such as small downgrades or slight concerns about a quarter’s performance. In these cases, he noted, the punishment rarely fits the crime, if a real issue even exists.
Cramer also recently weighed in on the ongoing trade tensions with China. He urged Wall Street to start taking President Trump’s policies more seriously, pointing out that Trump had negotiated a deal that granted China a much lower tariff than Canada received. Cramer dismissed the idea that China’s response was an equal counterattack, calling such a notion “nonsense” and “idiocy.” He added:
“Now, if Wall Street took Trump seriously, they’d know that China played softball with its retaliation just like Trump played softball with that 10% tariff.”
He elaborated that much of the recent panic, which had escalated on Sunday night, shifted a bit to optimism, as people began to realize that the president had managed to negotiate a deal. Acknowledging the presence of hardliners within the White House who are keen on taking a tougher stance on China, Cramer noted that those individuals had lost the battle.
He pointed out that Trump’s objective was to broker a deal that could generate revenue for the U.S. Treasury while providing American businesses with opportunities in China. Cramer emphasized that this goal should have been clear to anyone who had been watching the Chinese stock market, as stocks that trade in China surged recently.
Our Methodology
For this article, we compiled a list of 13 stocks that were discussed by Jim Cramer during the episode of Mad Money on February 5. We listed the stocks in the order that Cramer mentioned them. We also provided hedge fund sentiment for each stock as of the third quarter of 2024, which was taken from Insider Monkey’s database of 900 hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).
An operating room with a doctor monitoring a patient’s vital signs during surgery with a medical device.
Abbott Laboratories (NYSE:ABT)
Number of Hedge Fund Holders: 63
Abbott Laboratories (NYSE:ABT) is an international healthcare company dedicated to the discovery, development, production, and sale of a diverse range of healthcare products. Cramer highlighted how the company, despite its lawsuit, has been able to trek upward.
“And we saw this with Abbott Labs, ABT, not that long ago when it lost a lawsuit involving a special infant formula that some agree, parents thought harmed their baby. The formula was made by Abbott because women sometimes just can’t produce enough milk. Abbott only made $9 million a year on it.
I think that they actually own this formula. I think they do it at the behest of the government or just out of, literally out of their hearts, but it doesn’t matter. They lost a $500 million lawsuit, $500 million. And now I told you to dismiss it, not worry about it. Sure enough, what happened? Abbott stock is now up more than 30 points from that event.”
Overall ABT ranks 5th on our list of the stocks Jim Cramer highlighted recently. While we acknowledge the potential of ABT as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than ABT but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap
Disclosure: None. This article was originally published at Insider Monkey.
Hedge Fund Resource Center